SCHEDULE APPOINTMENT: CALL 800.999.1249 OR SCHEDULE ONLINE
ASTRAZENECA (FLASH) 18 – 88 YEARS OF AGE ASTHMA STUDY
If you are interested in participating and believe you meet the requirements, please contact our research staff to learn more at 502.368.0732.
Explore More About These Research Trials
An easy way to track when your study milestones, treatments, or updates are expected.
ASTRAZENECA (FLASH) 18 – 88 YEARS OF AGE {ASTHMA STUDY}
- Atuliflapon, is an oral selective FLAP inhibitor being developed for the treatment of asthma. Five-lipoxygenase activating protein (FLAP) is part of the 5-LO pathway that generates biologically active lipid mediators called leukotrienes.
- The purpose of this study is to assess the efficacy and safety of Multiple dose levels of Atuliflapon Given Orally Once Daily for twelve Weeks in Adults with Moderate to Severe Uncontrolled Asthma.
- Part 1 and Part 2: The overall study period is approximately 19 weeks; a 2-week Screening period, a 4-week run-in period, a 12-week treatment period, and a 1-week follow-up.
Key Inclusion:
- Participant must be 18 to 80 years
- Body weight ≥ 40 kg and BMI < 35 kg/m2
- Documented physician-diagnosed asthma ≥ 12 months prior to Screening (Visit 1).
Key Exclusion:
- Current smokers or participants with smoking history ≥ 10 pack-years.
- Treatment with marketed biologics including benralizumab, mepolizumab, reslizumab, omalizumab, and dupilumab within 6 months of Screening (Visit 1) or 5 half-lives
Explore More About These Research Trials
An easy way to track when your study milestones, treatments, or updates are expected.
Interested in hearing more about these Research Trials?
Please contact one of our staff at 502.368.0732 or fill out the form below: